Aventis and Sanofi-Synthelabo are set to merge after a tense three-month standoff. But at what price? Megan Murphy looks at whether a regulatory decision could leave French companies more vulnerable to takeover
To access our in-house intelligence please request a trial here.
Read this article – and more – for a one-week period.